歌禮制藥-B(01672.HK)公佈業績:2022年度研發費用增至2.67億元
格隆匯3月20日丨歌禮制藥-B(01672.HK)發佈公吿,截至2022年12月31日止年度,集團總收入同比減少29.6%至約人民幣5410萬元,原因是終止向羅氏製藥中國提供派羅欣®的推廣服務。於2022年12月31日,集團的現金及現金等價物約為人民幣24.708億元,預期足以支持其直至2027年的研發活動及營運。
集團的研發費用從2021年度的約人民幣2.133億元增加25.2%至2022年度的約人民幣2.671億元,主要因為集團的多個候選藥物推進至II期或III期的臨牀試驗及集團持續投資於研究與開發。
集團建立了一個覆蓋廣泛的資產管線,專注於病毒性疾病、非酒精性脂肪性肝炎╱PBC及腫瘤領域。於報吿期內及直至該公吿日期,集團成功取得中國國家藥監局和美國FDA的13項IND批准,使2項新候選藥物進入II期階段,並支持了6項候選藥物正在進行的II期或III期的臨牀開發。這種研發效率再次體現了與中國生物科技行業的同業相比集團卓越的運營水平。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.